SCHEMBL7144366

SCHEMBL7144366

Cc1ccc(COc2ccc(/C=C3\SC(=S)N(CC(=O)O)C3=O)c(OCc3ccc(C)cc3)c2)cc1

nearest known ligand 0.68

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 8/20 0.65
POLB P06746 8/20 0.65
KMT2A Q03164 8/20 0.65
PPARG P37231 1/20 0.65
PTPN1 P18031 5/20 0.61
AKR1B1 P15121 3/20 0.61
MMP3 P08254 2/20 0.61
MMP13 P45452 2/20 0.61
GFER P55789 2/20 0.61
NSD2 O96028 1/20 0.61
PLA2G1B P04054 1/20 0.61
DNMT1 P26358 1/20 0.61
ATG4B Q9Y4P1 1/20 0.61
ADAMTS5 Q9UNA0 1/20 0.58
BLM P54132 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7144369 1.00 MEN1 (0.65) MEN1POLBKMT2APPARGPTPN1
SCHEMBL7143698 0.94 MEN1 (0.67) MEN1POLBKMT2APPARGPTPN1
SCHEMBL7143702 0.94 MEN1 (0.67) MEN1POLBKMT2APPARGPTPN1
SCHEMBL7398219 0.93 MEN1 (0.65) MEN1POLBKMT2APTPN1AKR1B1
SCHEMBL7144808 0.93 MEN1 (0.65) MEN1POLBKMT2APTPN1AKR1B1
SCHEMBL7147356 0.92 PTPN1 (0.73) MEN1POLBKMT2APTPN1AKR1B1
SCHEMBL7145580 0.91 POLB (0.78) MEN1POLBKMT2APTPN1AKR1B1
SCHEMBL7399985 0.91 POLB (0.78) MEN1POLBKMT2APTPN1AKR1B1
SCHEMBL7148890 0.89 MEN1 (0.63) MEN1POLBKMT2APPARGPTPN1
SCHEMBL7149884 0.86 MEN1 (0.67) MEN1POLBKMT2APTPN1AKR1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6506755-B2 5-((2,4-bis-(4-methylphenylmethoxy)phenyl)methylene)-4-oxo-2-thioxo-3 -thiazolidineacetic acid, for example; treatment and prophylaxis of tumors and tumor metastasis HOFFMANN-LA ROCHE INC. 2003-01-14 US claimed
US-20020037901-A1 Thiazolidinecarboxyl acids HOFFMANN-LA ROCHE INC. 2002-03-28 US claimed
EP-1189894-A1 THIAZOLIDINE CARBOXYLIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER F. HOFFMANN-LA ROCHE AG (CH) 2002-03-27 EP claimed
WO-2001057006-A1 THIAZOLIDINE CARBOXYLIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER F. HOFFMANN-LA ROCHE AG (CH) 2001-08-09 WO claimed
US-6506755-B2 5-((2,4-bis-(4-methylphenylmethoxy)phenyl)methylene)-4-oxo-2-thioxo-3 -thiazolidineacetic acid, for example; treatment and prophylaxis of tumors and tumor metastasis HOFFMANN-LA ROCHE INC. 2003-01-14 US disclosed
US-20020037901-A1 Thiazolidinecarboxyl acids HOFFMANN-LA ROCHE INC. 2002-03-28 US disclosed
EP-1189894-A1 THIAZOLIDINE CARBOXYLIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER F. HOFFMANN-LA ROCHE AG (CH) 2002-03-27 EP disclosed
WO-2001057006-A1 THIAZOLIDINE CARBOXYLIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER F. HOFFMANN-LA ROCHE AG (CH) 2001-08-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020037901-A1 Thiazolidinecarboxyl acids TPMT, NAT1, THRA MEN1 936/4885POLB 3974/4885KMT2A 1605/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.